Company: AGIO
Filing Date: 2025-10-30
Form Type: 10-Q
Source: 0001439222-25-000116
Chunk: 117

Company: AGIOS PHARMACEUTICALS, INC.
Filing Date: 2025-10-30
Form: 10-Q
Item: Part I, Item 1
Chunk 117
---
284,330 1,540,956 Total liabilities and stockholders’ equity$1,385,705 $1,663,199 

See accompanying Notes to Condensed Consolidated Financial Statements.

1

Table of Contents    

AGIOS PHARMACEUTICALS, INC.

Condensed Consolidated Statements of Operations

(Unaudited)

Three Months Ended September 30,Nine Months Ended September 30,(In thousands, except share and per share data)2025202420252024Revenues:Product revenue, net$12,880 $8,964 $34,061 $25,768 Total revenue12,880 8,964 34,061 25,768 Operating expenses:Cost of sales$1,679 $783 $4,466 $2,905 Research and development86,796 72,455 251,479 218,476 Selling, general and administrative41,274 38,537 128,670 105,087 Total operating expenses129,749 111,775 384,615 326,468 Loss from operations(116,869)(102,811)(350,554)(300,700)Gain on sale of contingent payments— 889,136 — 889,136 Milestone payment from gain on sale of oncology business— 200,000 — 200,000 Interest income, net13,369 13,059 43,969 30,068 Other income, net67 1,651 1,843 4,864 Net (loss) income before taxes(103,433)1,001,035 (304,742)823,368 Income tax expense— 53,120 — 53,120 Net (loss) income$(103,433)$947,915 $(304,742)$770,248 Net (loss) income per share - basic$(1.78)$16.65 $(5.27)$13.58 Net (loss) income per share - diluted$(1.78)$16.22 $(5.27)$13.38 Weighted-average number of common shares used in computing net (loss) income per share – basic58,139,277 56,939,403 57,846,173 56,709,318 Weighted-average number of common shares used in computing net (loss) income per share – diluted